pI: 9.6906 |
Length (AA): 653 |
MW (Da): 75019 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_127396)
Species | Accession | Gene Product |
---|---|---|
Brugia malayi | Bm1_14075 | serine/threonine-protein kinase plk-2 |
Candida albicans | CaO19.13431 | protein serine/threonine kinase |
Candida albicans | CaO19.6010 | protein serine/threonine kinase |
Caenorhabditis elegans | CELE_F55G1.8 | Protein PLK-3 |
Caenorhabditis elegans | CELE_Y71F9B.7 | Protein PLK-2 |
Caenorhabditis elegans | CELE_C14B9.4 | Protein PLK-1, isoform B |
Dictyostelium discoideum | DDB_G0274503 | polo family protein kinase |
Drosophila melanogaster | Dmel_CG12306 | CG12306 gene product from transcript CG12306-RA |
Echinococcus granulosus | EgrG_000471700 | serine:threonine protein kinase PLK1 |
Entamoeba histolytica | EHI_008410 | serine/threonine protein kinase, putative |
Echinococcus multilocularis | EmuJ_000471700 | serine:threonine protein kinase PLK1 |
Giardia lamblia | GL50803_104150 | Kinase, PLK |
Homo sapiens | ENSG00000166851 | polo-like kinase 1 |
Homo sapiens | ENSG00000173846 | polo-like kinase 3 |
Homo sapiens | ENSG00000145632 | polo-like kinase 2 |
Leishmania braziliensis | LbrM.17.0690 | protein kinase, putative,polo-like protein kinase, putative |
Leishmania infantum | LinJ.17.0770 | protein kinase, putative,polo-like protein kinase, putative |
Leishmania major | LmjF.17.0790 | protein kinase, putative,polo-like protein kinase, putative |
Leishmania mexicana | LmxM.17.0790 | protein kinase, putative,polo-like protein kinase, putative |
Loa Loa (eye worm) | LOAG_00597 | PLK/PLK1 protein kinase |
Mus musculus | ENSMUSG00000021701 | polo-like kinase 2 |
Mus musculus | ENSMUSG00000030867 | polo-like kinase 1 |
Mus musculus | ENSMUSG00000028680 | polo-like kinase 3 |
Onchocerca volvulus | OVOC6373 | Serine\/threonine kinase homolog |
Saccharomyces cerevisiae | YMR001C | polo kinase CDC5 |
Schistosoma japonicum | Sjp_0214990 | Serine/threonine-protein kinase PLK1, putative |
Schistosoma japonicum | Sjp_0117190 | ko:K06631 polo-like kinase 1, putative |
Schistosoma mansoni | Smp_009600 | serine/threonine protein kinase |
Schmidtea mediterranea | mk4.003234.06 | Probable serine/threonine-protein kinase zyg-1 |
Schmidtea mediterranea | mk4.002811.01 | |
Schmidtea mediterranea | mk4.007361.02 | Serine/threonine kinase |
Schmidtea mediterranea | mk4.002305.03 | Inactive serine/threonine-protein kinase PLK5 |
Schmidtea mediterranea | mk4.001509.00 | Serine/threonine kinase |
Schmidtea mediterranea | mk4.003052.00 | Serine/threonine kinase |
Trypanosoma brucei gambiense | Tbg972.7.7280 | polo-like protein kinase,protein kinase |
Trypanosoma brucei | Tb927.7.6310 | polo-like protein kinase |
Trypanosoma congolense | TcIL3000_7_5220 | protein kinase, putative |
Trypanosoma cruzi | TcCLB.506513.160 | polo-like protein kinase, putative |
Trypanosoma cruzi | TcCLB.508917.10 | polo-like protein kinase, putative |
Trichomonas vaginalis | TVAG_039910 | CAMK family protein kinase |
Trichomonas vaginalis | TVAG_069810 | CAMK family protein kinase |
Trichomonas vaginalis | TVAG_432460 | CAMK family protein kinase |
Trichomonas vaginalis | TVAG_088660 | CAMK family protein kinase |
Trichomonas vaginalis | TVAG_003370 | CAMK family protein kinase |
Trichomonas vaginalis | TVAG_279730 | CAMK family protein kinase |
Trichomonas vaginalis | TVAG_107500 | CAMK family protein kinase |
Trichomonas vaginalis | TVAG_083120 | CAMK family protein kinase |
Trichomonas vaginalis | TVAG_496190 | CAMK family protein kinase |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.7.6310 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.7.6310 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.7.6310 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.7.6310 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_C14B9.4 | Caenorhabditis elegans | adult lethal | wormbase |
CELE_C14B9.4 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_C14B9.4 | Caenorhabditis elegans | larval lethal | wormbase |
CELE_C14B9.4 | Caenorhabditis elegans | sterile | wormbase |
CELE_Y71F9B.7 | Caenorhabditis elegans | sterile | wormbase |
YMR001C | Saccharomyces cerevisiae | inviable | yeastgenome |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | polo-like kinase 2 | Compounds | References |
Homo sapiens | polo-like kinase 1 | Compounds | References |
Xenopus laevis | Serine/threonine-protein kinase PLK1 | Compounds | References |
Homo sapiens | polo-like kinase 3 | Compounds | References |
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Xenopus laevis | Aurora kinase B-B | 368 aa | 32.5% | 308 aa | Compounds | References |
Rattus norvegicus | Cell division protein kinase 5 | 292 aa | 27.3% | 286 aa | Compounds | References |
Rattus norvegicus | Serine/threonine-protein kinase pim-3 | 326 aa | 28.1% | 267 aa | Compounds | References |
Sus scrofa | Casein kinase I isoform alpha | 125 aa | 28.7% | 122 aa | Compounds | References |
Oryctolagus cuniculus | Cyclin-dependent kinase 4 | 189 aa | 27.5% | 160 aa | Compounds | References |
Plasmodium falciparum (isolate 3D7) | Cell division control protein 2 homolog | 288 aa | 29.5% | 281 aa | Compounds | References |